BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8077983)

  • 1. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo MJ
    J Chemother; 1994 Apr; 6(2):102-6. PubMed ID: 8077983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
    Alişkan H; Turunç T; Demiroğlu YZ; Colakoğlu S; Arslan H
    Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
    Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey.
    Yamazhan T; Aydemir S; Tünger A; Serter D; Gökengin D
    Med Princ Pract; 2005; 14(6):413-6. PubMed ID: 16220015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey.
    Kocagöz S; Akova M; Altun B; Gür D; Hasçelik G
    Clin Microbiol Infect; 2002 Apr; 8(4):240-2. PubMed ID: 12047416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.
    Kilic S; Dizbay M; Cabadak H
    J Chemother; 2008 Feb; 20(1):33-7. PubMed ID: 18390405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
    Khan MY; Dizon M; Kiel FW
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1409-10. PubMed ID: 2802568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
    Qadri SM; Ueno Y; Ayub A
    Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Brucella melitensis to fluoroquinolones.
    Qadri SM; Akhtar M; Ueno Y; al-Sibai MB
    Drugs Exp Clin Res; 1989; 15(10):483-5. PubMed ID: 2632216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of six new fluoroquinolones against Brucella melitensis.
    Trujillano-Martín I; García-Sánchez E; Martínez IM; Fresnadillo MJ; García-Sánchez JE; García-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Jan; 43(1):194-5. PubMed ID: 9869594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of lomefloxacin against Brucella melitensis.
    Qadri SM; al-Sedairy S; Ueno Y
    Diagn Microbiol Infect Dis; 1990; 13(3):277-9. PubMed ID: 2383977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
    Qadri SM; Ueno Y
    Chemotherapy; 1993; 39(2):128-31. PubMed ID: 8384544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.